Adding the targeted drug savolitinib to osimertinib, sold as Tagrisso, significantly delayed disease progression compared with osimertinib alone in previously untreated patients with EGFR-mutated, MET-overexpressing non-small cell lung cancer, according to topline results announced by HUTCHMED from the phase 3 SANOVO trial.
The relevance for American patients is real but indirect, and the qualifiers matter more than the headline. SANOVO was conducted entirely in China. The combination is not approved in the United States for this use. No efficacy figures have been released. Nothing about this changes what a U.S. oncologist can prescribe this week.
